Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XL228 是一种多靶点酪氨酸激酶抑制剂,对 Bcr-Abl、Aurora A、IGF-1R、Src 和 Lyn 的 IC50 分别为 5、3.1、1.6、6.1和 2 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 467 | 现货 | ||
2 mg | ¥ 679 | 现货 | ||
5 mg | ¥ 976 | 现货 | ||
10 mg | ¥ 1,390 | 现货 | ||
25 mg | ¥ 2,450 | 现货 | ||
50 mg | ¥ 3,870 | 现货 | ||
100 mg | ¥ 5,590 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,080 | 现货 |
产品描述 | XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively). |
靶点活性 | Aurora A:3.1 nM, IGF-1R:1.6 nM |
体外活性 | XL228 inhibits phosphorylation of BCR-ABL and its substrate STAT5 in K562 cells in vitro (IC50s: 33 and 43 nM, respectively). XL228 eliminates the phosphorylation of Aurora A and B at concentrations above 10 nM. XL228 displays a broad pattern of protein kinase inhibition, including the tyrosine kinases IGF1R, SRC, ABL, FGFR1-3, and ALK and the serine/threonine kinases Aurora A and Aurora B. Approximately 30% of the lines demonstrate XL228 IC50 values of <100nM in viability assays, including many lines with characterized ALK or FGFR mutations or amplifications [2][3]. |
体内活性 | Single-dose pharmacodynamics studies demonstrate that XL228 on BCR-ABL signaling in K562 xenograft tumors has a potent effect. At XL228 plasma concentrations of 3.5 μM, phosphorylation of BCR-ABL is decreased by 50%; a similar decrease in phospho-STAT5 occurred at 0.8 μM plasma concentration [3]. |
分子量 | 437.54 |
分子式 | C22H31N9O |
CAS No. | 898280-07-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (190.45 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2855 mL | 11.4275 mL | 22.8551 mL | 57.1376 mL |
5 mM | 0.4571 mL | 2.2855 mL | 4.571 mL | 11.4275 mL | |
10 mM | 0.2286 mL | 1.1428 mL | 2.2855 mL | 5.7138 mL | |
20 mM | 0.1143 mL | 0.5714 mL | 1.1428 mL | 2.8569 mL | |
50 mM | 0.0457 mL | 0.2286 mL | 0.4571 mL | 1.1428 mL | |
100 mM | 0.0229 mL | 0.1143 mL | 0.2286 mL | 0.5714 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
XL228 898280-07-4 Angiogenesis Cell Cycle/Checkpoint Chromatin/Epigenetic Cytoskeletal Signaling Tyrosine Kinase/Adaptors IGF-1R Bcr-Abl Src Aurora Kinase Inhibitor XL 228 XL-228 inhibit inhibitor